Emerging lipid nanoparticle systems capable of efficient intramuscular RNA delivery

Area of Science:

• Biotechnology
• Nanomedicine
• Vaccinology

Background:

• Lipid nanoparticles (LNPs) are crucial for RNA delivery, notably in mRNA vaccines like those for COVID-19.
• They utilize ionizable lipids for endosomal escape and PEG-lipids for stability.
• Intramuscular (IM) injection is a common administration route, leveraging local immune responses.

Purpose of the Study:

• To review the role and advancements of LNPs in RNA delivery.
• To discuss challenges and future directions in LNP formulation and application.
• To highlight the expanding therapeutic potential of LNPs.

Main Methods:

• Review of current literature on LNP technology and RNA delivery.
• Analysis of LNP components (ionizable lipids, PEG-lipids) and their functions.
• Exploration of administration routes and their implications.
• Discussion of emerging LNP innovations and AI-driven platforms.

Main Results:

• LNPs have enabled significant breakthroughs in vaccine development.
• IM administration of LNPs offers localized antigen production and reduced systemic toxicity.
• Key challenges include cold-chain dependence, RNA instability, and potential immunogenicity.
• Advancements focus on AI, hybrid systems, and stimuli-responsive formulations for enhanced stability and controlled release.

Conclusions:

• LNPs are evolving from emergency tools to versatile platforms for diverse RNA therapeutics.
• Future innovations promise improved accessibility, safety, and efficacy for genetic disorders, infectious diseases, and precision oncology.
• Interdisciplinary research is key to unlocking the full potential of LNPs in medicine.